AI English summary of an SEC filing — figures as filed
Baxter International BAXBaxter said first-quarter Q1 2025 sales from continuing operations totaled approximately $2.63 billion, increasing 5% on both a reported and operational basis. U.S. sales were approximately $1.49 billion, up 11% on a reported basis, while international sales were approximately $1.14 billion, down 1% on a reported basis.
Key points
AI summaryBaxter said first-quarter Q1 2025 sales from continuing operations totaled approximately $2.63 billion, increasing 5% on both a reported and operational basis. U.S. sales were approximately $1.49 billion, up 11% on a reported basis, while international sales were approximately $1.14 billion, down 1% on a reported basis.
The company said U.S. GAAP net income from continuing operations for Q1 2025 totaled $64 million, or $0.13 per diluted share, and adjusted diluted earnings per share from continuing operations was $0.55. The company's prior guidance was $0.47 to $0.50 per diluted share.
Baxter said segment sales for Q1 2025 were Medical Products & Therapies approximately $1.26 billion, up 3% on a reported basis; Healthcare Systems & Technologies approximately $704 million, up 6%; and Pharmaceuticals approximately $581 million, up 1%.
The company raised the bottom end of its previous range for full-year 2025 adjusted diluted earnings per share from continuing operations guidance and now expects $2.47 to $2.55, compared to prior guidance of $2.45 to $2.55. For Q2, the company expects adjusted diluted earnings per share of $0.59 to $0.63.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
First-Quarter Q1 2025 Continuing Operations Sales $2.63 billion
Baxter said first-quarter Q1 2025 sales from continuing operations totaled approximately $2.63 billion, increasing 5% on both a reported and operational basis. U.S. sales were approximately $1.49 billion, up 11% on a reported basis, while international sales were approximately $1.14 billion, down 1% on a reported basis.
Source · Based on the filing body and exhibits
Q1 GAAP Continuing Operations Net Income $64 million, Adjusted EPS $0.55
The company said U.S. GAAP net income from continuing operations for Q1 2025 totaled $64 million, or $0.13 per diluted share, and adjusted diluted earnings per share from continuing operations was $0.55. The company's prior guidance was $0.47 to $0.50 per diluted share.
Source · Based on the filing body and exhibits
Q1 Segment Sales: Medical Products & Therapies and Others
Baxter said segment sales for Q1 2025 were Medical Products & Therapies approximately $1.26 billion, up 3% on a reported basis; Healthcare Systems & Technologies approximately $704 million, up 6%; and Pharmaceuticals approximately $581 million, up 1%.
Source · Based on the filing body and exhibits
Full-Year 2025 Adjusted EPS Guidance $2.47 to $2.55
The company raised the bottom end of its previous range for full-year 2025 adjusted diluted earnings per share from continuing operations guidance and now expects $2.47 to $2.55, compared to prior guidance of $2.45 to $2.55. For Q2, the company expects adjusted diluted earnings per share of $0.59 to $0.63.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…